Skip to main
  1. Stocks
  2. Guardian Pharmacy Services Inc
  3. Forecast
GRDN

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Service is viewed positively because it is the clear leader in a fragmented LTC pharmacy market, with 13% national share, over 200,000 residents served, and a purpose-built model for assisted living that creates scale, pricing, and service advantages versus smaller peers. Its outlook is further supported by durable demographic demand as baby boomers age into assisted living, plus a three-pronged growth engine that can drive high-single-digit organic growth through deeper penetration, new contracts, and greenfield expansion. Financially, the company’s balance sheet is a strength, with about $90 million of cash, no debt, ~60% cash conversion, and best-in-class ex-cash ROIC of roughly 35%-40%, while 2024 and 2025 acquisitions and openings representing ~10% of revenue could add a 3%-4% EBITDA tailwind in 2027 and 2028.

Bears say

Guardian Pharmacy Service is facing a structurally weaker reimbursement backdrop as the IRA and CMS pricing changes push certain high-cost branded drugs toward Maximum Fair Prices, which can fall below pharmacies’ acquisition costs and compress margins even after manufacturer true-ups. The pressure is especially relevant in long-term care, where profitability has historically depended on branded drugs despite them representing only about 10% of volume, while generic drugs make up roughly 90% of volume and earn breakeven margins. In addition, the bankruptcy of Omnicare in September 2025 highlights regulatory and reimbursement vulnerability across the sector, while risks around staffing, PBM contracts, facility integration, and reliance on technology assets add further downside to fundamentals.

GRDN has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

GRDN Analyst Forecast & Price Prediction

Get the latest GRDN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GRDN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Buy based on their latest research and market trends.

According to 6 analysts, GRDN has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


GRDN Analyst Forecast & Price Prediction

Get the latest GRDN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GRDN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GRDN stock data and trends